Now Approved as Tablets: Available Early October 2025
WM is caused by rapid growth and spread of cancerous B cells.
The significance of blocking up to 100% of BTK on treatment responses has not been established.
BRUKINSA’s effectiveness was assessed in a clinical trial. The aim of that study was to compare BRUKINSA with ibrutinib, another FDA-approved BTK inhibitor, to see if BRUKINSA achieved better treatment responses for people with Waldenström’s macroglobulinemia.
The trial included 201 people who were either newly diagnosed with, or who had received at least one prior treatment for, WM.
Although BRUKINSA did not achieve a better combined treatment response than ibrutinib, as both BRUKINSA and ibrutinib had a 78% combined response rate—complete response (CR) + very good partial response (VGPR) + partial response (PR)—BRUKINSA did show a higher very good partial response: 16% for BRUKINSA and 7% for ibrutinib. In addition, 95% of patients on BRUKINSA continued to respond for a year or longer and 89% of patients on ibrutinib continued to respond for a year or longer, after a median follow-up of 19.4 months.
Neither treatment had a complete response in this study.
The study included people who had been previously treated for WM and those who had not, as well as people with and without certain genetic mutations: MYD88MUT, MYD88WT, CXCR4WT, and CXCR4WHIM. In the exploratory analysis of 26 MYD88WT patients who received BRUKINSA, 50% had either a very good partial response or partial response and 27% had a very good partial response.
Results were consistent across each of these groups.
It is important to know that a response, even a very good partial response, does not mean the cancer has been cured.
Treatment Response Category | Definition |
---|---|
Complete response (CR) | The disease has completely responded to treatment and there are no symptoms or signs of WM |
Very good partial response (VGPR) | A small amount of disease can be detected, and there are no new symptoms or signs of WM |
Partial response (PR) | The disease is still detectable, but there are no new symptoms or signs of WM |
These are not all the possible side effects of BRUKINSA. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
If side effects occur, partnering with your doctor can help you manage any symptoms you may experience and may help ensure you can continue treatment with BRUKINSA.
How long will I be on treatment with BRUKINSA? |
---|
You will take BRUKINSA for as long as your doctor thinks it is helping you, or for as long as side effects are manageable. Remember, everyone responds differently to treatment, so the length of time that you take BRUKINSA could be shorter or longer. |
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking BRUKINSA with certain other medications may affect how BRUKINSA works and can cause side effects.
These are not all the possible side effects of BRUKINSA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
BRUKINSA is a prescription medicine used to treat adults with:
It is not known if BRUKINSA is safe and effective in children.
Please see full Prescribing Information including Patient Information.